Statins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection.
Saved in:
| Title: | Statins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection. |
|---|---|
| Authors: | Gupta, Muskaan (AUTHOR), Smokovski, Ivica (AUTHOR), Chatzis, Dimitrios G. (AUTHOR), Spring, Kevin J. (AUTHOR), Mehndiratta, Man Mohan (AUTHOR), Beran, Roy G. (AUTHOR), Bhaskar, Sonu M. M. (AUTHOR) |
| Source: | CNS Drugs. Nov2025, Vol. 39 Issue 11, p1083-1107. 25p. |
| Subjects: | Statins (Cardiovascular agents), Ischemic stroke, Stroke patients, Neuroprotective agents, Cognition disorders, Pharmacogenomics, Individualized medicine, Biomarkers |
| Abstract: | Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline. Key challenges limiting the full therapeutic potential of statins include interindividual variability in response and pharmacogenomic and biomarker-related resistance, inconsistencies across clinical guidelines, and limited central nervous system bioavailability. Innovations such as pharmacogenomic-guided therapy, pleiotropy-linked biomarkers, and advanced drug delivery systems (e.g., nanoparticle and intranasal formulations) may help overcome these barriers. Combination strategies with agents such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors or sodium–glucose cotransporter 2 (SGLT2) inhibitors, and targeted interventions against neuroinflammatory resistance, show promise in enhancing treatment efficacy. In doing so, we propose a shift from conventional statin use to a precision medicine paradigm that can better serve AIS survivors, especially those at risk of post-stroke dementia or those living in resource-constrained settings. While such innovations, for example, genetic testing and novel delivery methods, may not yet be feasible in all contexts, particularly low-resource environments, they represent long-term goals for equity-driven innovation. Equity in access to high-intensity statins and novel therapies remains a global priority, particularly in low- and middle-income countries. Future research should prioritize personalized, biomarker-driven approaches and inclusive clinical trials to optimize statin use across diverse AIS populations. By advancing these strategies, statins can evolve from cardiovascular agents into integral components of precision neurovascular medicine, improving long-term outcomes and quality of life for stroke survivors. Plain Language Summary: Stroke is a leading cause of death and disability worldwide. After a stroke, patients are at high risk of having another stroke, developing heart problems, or experiencing long-term difficulties with memory and thinking, often referred to as post-stroke dementia. This article explores how a group of medications called statins, commonly used to lower cholesterol, may offer additional benefits beyond cholesterol reduction. Recent research suggests that statins have "pleiotropic" effects, meaning that they can reduce inflammation, stabilize blood vessels, and potentially support brain recovery after a stroke. These effects may help lower the risk of further strokes, reduce mortality, and protect against post-stroke cognitive decline. However, the evidence for cognitive benefits remains mixed, and further high-quality clinical trials are needed. Importantly, statins do not work equally well for everyone. Some patients experience limited benefits or side effects. This article discusses emerging strategies in stroke care, including the use of genetic tests and biomarkers to predict individual responses to statin therapy. It also highlights innovative delivery methods, such as nasal sprays or nanoparticles, that may help statins reach the brain more effectively. We propose moving away from a one-size-fits-all approach toward personalized treatment that considers a patient's stroke subtype, genetic profile, and overall health. This approach could be especially valuable in low-resource settings where access to specialized stroke care is limited. If adopted more broadly, these strategies may help statins evolve from cardiovascular drugs into tools that also support brain health after stroke. [ABSTRACT FROM AUTHOR] |
| Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
Be the first to leave a comment!
